MYC and lymphoma: By targeting MYC, JQ1 showed anticancer activity in several cancer types including Merkel cell carcinoma [160], esophageal squamous cell carcinoma [161], and EBV-positive nasopharyngeal carcinoma [162], as well as in a variety of leukemias and lymphomas [163,164,165].